Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer - PubMed (original) (raw)
. 2001 Apr 1;61(7):3212-9.
Affiliations
- PMID: 11306511
Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer
J Lukas et al. Cancer Res. 2001.
Abstract
mdm2 is part of a complex mechanism that regulates the expression of p53 as well as the function of Rb, p19ARF, and other genes. In humans, mdm2 dysregulation is associated with gene amplification. This study was undertaken to characterize altered mdm2 expression in a cohort of 38 invasive breast cancers and 9 normal breast specimens. Reverse-transcription PCR with primers spanning the entire open reading frame of the mdm2 gene in breast tissue RNA samples generated PCR products of full-length mdm2 (1526 bp) as well as smaller products (653, 281, 254, and 219 bp). Sequence analysis demonstrated that the 653-bp product was an alternatively spliced product (defined as splicing at the exon/intron boundary consensus sites), whereas the 281, 254, and 219 bp mdm2 products were aberrantly spliced products (splicing at sites not considered to be exon/intron boundary sites). Reverse-transcription-PCR with normal breast tissue RNA samples yielded only the 1526-bp product in five samples and the 1526-bp product and the 653-bp product in four samples. The 653-bp alternatively spliced product was expressed in 21% of breast cancers, and the smaller, aberrantly spliced mRNA products (281 bp, 254 bp, and/or 219 bp) were expressed in 16% of breast cancers. The protein products predicted by the alternatively spliced mRNAs and the aberrantly spliced mRNAs lacked either the entire binding domain for p53 or the majority of the binding domain for p53. Immunohistochemical analysis of HER2/neu (c-erbB2), estrogen receptor, progesterone receptor, epidermal growth factor receptor, and p53 protein was performed. p53 sequence alterations were identified by mismatch detection and confirmed by p53 oligonucleotide microarray technology. An association was demonstrated between the expression of aberrantly and/or alternatively spliced mdm2 mRNAs and a lack of progesterone receptor. An association was also demonstrated between mdm2 aberrantly and/or alternatively expression products and the presence of p53 tumor suppressor gene mutations. mdm2 is transcribed from two different promoters: one, p53-dependent, and the other, p53-independent. The 5' untranslated region of the transcripts was evaluated to determine the promoter usage in each breast cancer specimen. No correlation was observed between mdm2 splice products and promoter usage. The presence of aberrant expression products of mdm2 in breast cancer specimens was correlated with a shortened overall patient survival. These observations suggest that mdm2 expression is altered in invasive breast cancer and is associated with more aggressive disease.
Similar articles
- Expression of alternatively and aberrantly spliced transcripts of the MDM2 mRNA is not tumor-specific.
Bartel F, Pinkert D, Fiedler W, Kappler M, Würl P, Schmidt H, Taubert H. Bartel F, et al. Int J Oncol. 2004 Jan;24(1):143-51. doi: 10.3892/ijo.24.1.143. Int J Oncol. 2004. PMID: 14654951 - Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
Tamborini E, Della Torre G, Lavarino C, Azzarelli A, Carpinelli P, Pierotti MA, Pilotti S. Tamborini E, et al. Int J Cancer. 2001 Jun 15;92(6):790-6. doi: 10.1002/ijc.1271. Int J Cancer. 2001. PMID: 11351297 - Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H. Matsumoto R, et al. Cancer Res. 1998 Feb 15;58(4):609-13. Cancer Res. 1998. PMID: 9485008 - Alternative and aberrant splicing of MDM2 mRNA in human cancer.
Bartel F, Taubert H, Harris LC. Bartel F, et al. Cancer Cell. 2002 Jul;2(1):9-15. doi: 10.1016/s1535-6108(02)00091-0. Cancer Cell. 2002. PMID: 12150820 Review. - MDM2 and MDM4 splicing: an integral part of the cancer spliceome.
Jeyaraj S, O'Brien DM, Chandler DS. Jeyaraj S, et al. Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2647-56. doi: 10.2741/3402. Front Biosci (Landmark Ed). 2009. PMID: 19273224 Review.
Cited by
- Comprehensive regulatory networks for tomato organ development based on the genome and RNAome of MicroTom tomato.
Xue JY, Fan HY, Zeng Z, Zhou YH, Hu SY, Li SX, Cheng YJ, Meng XR, Chen F, Shao ZQ, Van de Peer Y. Xue JY, et al. Hortic Res. 2023 Jul 19;10(9):uhad147. doi: 10.1093/hr/uhad147. eCollection 2023 Sep. Hortic Res. 2023. PMID: 37691964 Free PMC article. - Chronic Exposure to Nitric Oxide Induces P53 Mutations and Malignant-like Features in Human Breast Epithelial Cells.
Cheng RYS, Burkett S, Ambs S, Moody T, Wink DA, Ridnour LA. Cheng RYS, et al. Biomolecules. 2023 Feb 7;13(2):311. doi: 10.3390/biom13020311. Biomolecules. 2023. PMID: 36830680 Free PMC article. - Integrative Data Analytic Framework to Enhance Cancer Precision Medicine.
Gaudelet T, Malod-Dognin N, Pržulj N. Gaudelet T, et al. Netw Syst Med. 2021 Mar 18;4(1):60-73. doi: 10.1089/nsm.2020.0015. eCollection 2021. Netw Syst Med. 2021. PMID: 33796878 Free PMC article. - Regulation of p53 by E3s.
Pan M, Blattner C. Pan M, et al. Cancers (Basel). 2021 Feb 11;13(4):745. doi: 10.3390/cancers13040745. Cancers (Basel). 2021. PMID: 33670160 Free PMC article. Review. - Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors.
Hegde M, Joshi MB. Hegde M, et al. J Cancer Res Clin Oncol. 2021 Apr;147(4):937-971. doi: 10.1007/s00432-021-03519-4. Epub 2021 Feb 18. J Cancer Res Clin Oncol. 2021. PMID: 33604794 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous